|
1
|
Stein U, Arlt F, Walther W, Smith J,
Waldman T, Harris ED, Mertins SD, Heizmann CW, Allard D, Birchmeier
W, et al: The metastasis-associated gene S100A4 is a novel target
of beta-catenin/T-cell factor signaling in colon cancer.
Gastroenterology. 131:1486–1500. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ito M and Kizawa K: Expression of
calcium-binding S100 proteins A4 and A6 in regions of the
epithelial sac associated with the onset of hair follicle
regeneration. J Invest Dermatol. 116:956–963. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mazzucchelli L: Protein S100A4: Too long
overlooked by pathologists? Am J Pathol. 160:7–13. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Morris RJ, Liu Y, Marles L, Yang Z,
Trempus C, Li S, Lin JS, Sawicki JA and Cotsarelis G: Capturing and
profiling adult hair follicle stem cells. Nat Biotechnol.
22:411–417. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tumbar T, Guasch G, Greco V, Blanpain C,
Lowry WE, Rendl M and Fuchs E: Defining the epithelial stem cell
niche in skin. Science. 303:359–363. 2004. View Article : Google Scholar
|
|
6
|
Grum-Schwensen B, Klingelhofer J, Berg CH,
El-Naaman C, Grigorian M, Lukanidin E and Ambartsumian N:
Suppression of tumor development and metastasis formation in mice
lacking the S100A4(mts1) gene. Cancer Res. 65:3772–3780. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Saleem M, Kweon MH, Johnson JJ, Adhami VM,
Elcheva I, Khan N, Bin Hafeez B, Bhat KM, Sarfaraz S, Reagan-Shaw
S, et al: S100A4 accelerates tumorigenesis and invasion of human
prostate cancer through the transcriptional regulation of matrix
metalloproteinase 9. Proc Natl Acad Sci USA. 103:14825–14830. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mahon PC, Baril P, Bhakta V, Chelala C,
Caulee K, Harada T and Lemoine NR: S100A4 contributes to the
suppression of BNIP3 expression, chemoresistance, and inhibition of
apoptosis in pancreatic cancer. Cancer Res. 67:6786–6795. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lau LF and Lam SC: The CCN family of
angiogenic regulators: The integrin connection. Exp Cell Res.
248:44–57. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Holbourn KP, Acharya KR and Perbal B: The
CCN family of proteins: Structure-function relationships. Trends
Biochem Sci. 33:461–473. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kireeva ML, Mo FE, Yang GP and Lau LF:
Cyr61, a product of a growth factor-inducible immediate-early gene,
promotes cell proliferation, migration, and adhesion. Mol Cell
Biol. 16:1326–1334. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schütze N, Schenk R, Fiedler J, Mattes T,
Jakob F and Brenner RE: CYR61/CCN1 and WISP3/CCN6 are
chemoattractive ligands for human multipotent mesenchymal stroma
cells. BMC Cell Biol. 8:452007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lin BR, Chang CC, Chen LR, Wu MH, Wang MY,
Kuo IH, Chu CY, Chang KJ, Lee PH, Chen WJ, et al: Cysteine-rich 61
(CCN1) enhances chemotactic migration, transendothelial cell
migration, and intravasation by concomitantly up-regulating
chemokine receptor 1 and 2. Mol Cancer Res. 5:1111–1123. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
O'Brien TP and Lau LF: Expression of the
growth factor-inducible immediate early gene cyr61 correlates with
chondrogenesis during mouse embryonic development. Cell Growth
Differ. 3:645–654. 1992.PubMed/NCBI
|
|
15
|
Dornbach LM and Lyons KM: Genetic analysis
of CCN gene function in mammalian development. CCN Proteins. A New
Damily of Cell Growth and Differentiation Regulators. Perbal BV and
Takigawa M: Imperial College Press; London; Hackensack, NJ: pp.
135–152. 2005, View Article : Google Scholar
|
|
16
|
Brigstock DR: Regulation of angiogenesis
and endothelial cell function by connective tissue growth factor
(CTGF) and cysteine-rich 61 (CYR61). Angiogenesis. 5:153–165. 2002.
View Article : Google Scholar
|
|
17
|
Sun ZJ, Wang Y, Cai Z, Chen PP, Tong XJ
and Xie D: Involvement of Cyr61 in growth, migration, and
metastasis of prostate cancer cells. Br J Cancer. 99:1656–1667.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xie D, Miller CW, O'Kelly J, Nakachi K,
Sakashita A, Said JW, Gornbein J and Koeffler HP: Breast cancer.
Cyr61 is over-expressed, estrogen-inducible, and associated with
more advanced disease. J Biol Chem. 276:14187–14194.
2001.PubMed/NCBI
|
|
19
|
Xie D, Yin D, Tong X, O'Kelly J, Mori A,
Miller C, Black K, Gui D, Said JW and Koeffler HP: Cyr61 is
overexpressed in gliomas and involved in integrin-linked
kinase-mediated Akt and beta-catenin-TCF/Lef signaling pathways.
Cancer Res. 64:1987–1996. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kok SH, Chang HH, Tsai JY, Hung HC, Lin
CY, Chiang CP, Liu CM and Kuo MY: Expression of Cyr61 (CCN1) in
human oral squamous cell carcinoma: An independent marker for poor
prognosis. Head Neck. 32:1665–1673. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Holloway SE, Beck AW, Girard L, Jaber MR,
Barnett CC Jr, Brekken RA and Fleming JB: Increased expression of
Cyr61 (CCN1) identified in peritoneal metastases from human
pancreatic cancer. J Am Coll Surg. 200:371–377. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen PP, Li WJ, Wang Y, Zhao S, Li DY,
Feng LY, Shi XL, Koeffler HP, Tong XJ and Xie D: Expression of
Cyr61, CTGF, and WISP-1 correlates with clinical features of lung
cancer. PLoS One. 2:e5342007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chien W, Kumagai T, Miller CW, Desmond JC,
Frank JM, Said JW and Koeffler HP: Cyr61 suppresses growth of human
endometrial cancer cells. J Biol Chem. 279:53087–53096. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Evtimova V, Zeillinger R and Weidle UH:
Identification of genes associated with the invasive status of
human mammary carcinoma cell lines by transcriptional profiling.
Tumour Biol. 24:189–198. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Goodwin CR, Lal B, Zhou X, Ho S, Xia S,
Taeger A, Murray J and Laterra J: Cyr61 mediates hepatocyte growth
factor-dependent tumor cell growth, migration, and Akt activation.
Cancer Res. 70:2932–2941. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fekete M, Wittliff JL and Schally AV:
Characteristics and distribution of receptors for
[D-TRP6]-luteinizing hormone-releasing hormone, somatostatin,
epidermal growth factor, and sex steroids in 500 biopsy samples of
human breast cancer. J Clin Lab Anal. 3:137–147. 1989. View Article : Google Scholar
|
|
27
|
Baumann KH, Kiesel L, Kaufmann M, Bastert
G and Runnebaum B: Characterization of binding sites for a
GnRH-agonist (buserelin) in human breast cancer biopsies and their
distribution in relation to tumor parameters. Breast Cancer Res
Treat. 25:37–46. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Moriya T, Suzuki T, Pilichowska M, Ariga
N, Kimura N, Ouchi N, Nagura H and Sasano H: Immunohistochemical
expression of gonadotropin releasing hormone receptor in human
breast carcinoma. Pathol Int. 51:333–337. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mangia A, Tommasi S, Reshkin SJ, Simone G,
Stea B, Schittulli F and Paradiso A: Gonadotropin releasing hormone
receptor expression in primary breast cancer: Comparison of
immunohistochemical, radioligand and western blot analyses. Oncol
Rep. 9:1127–1132. 2002.PubMed/NCBI
|
|
30
|
Fost C, Duwe F, Hellriegel M, Schweyer S,
Emons G and Grundker C: Targeted chemotherapy for triple-negative
breast cancers via LHRH receptor. Oncol Rep. 25:1481–1487.
2011.PubMed/NCBI
|
|
31
|
von Alten J, Fister S, Schulz H, Viereck
V, Frosch KH, Emons G and Gründker C: GnRH analogs reduce
invasiveness of human breast cancer cells. Breast Cancer Res Treat.
100:13–21. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Schubert A, Hawighorst T, Emons G and
Gründker C: Agonists and antagonists of GnRH-I and −II reduce
metastasis formation by triple-negative human breast cancer cells
in vivo. Breast Cancer Res Treat. 130:783–790. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gründker C, Schlotawa L, Viereck V, Eicke
N, Horst A, Kairies B and Emons G: Antiproliferative effects of the
GnRH antagonist cetrorelix and of GnRH-II on human endometrial and
ovarian cancer cells are not mediated through the GnRH type I
receptor. Eur J Endocrinol. 151:141–149. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ziegler E, Hansen MT, Haase M, Emons G and
Gründker C: Generation of MCF-7 cells with aggressive metastatic
potential in vitro and in vivo. Breast Cancer Res Treat.
148:269–277. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gründker C, Bauerschmitz G, Knapp J,
Schmidt E, Olbrich T and Emons G: Inhibition of SDF-1/CXCR4-induced
epithelial-mesenchymal transition by kisspeptin-10. Breast Cancer
Res Treat. 152:41–50. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Olbrich T, Ziegler E, Türk G, Schubert A,
Emons G and Gründker C: Kisspeptin-10 inhibits bone-directed
migration of GPR54-positive breast cancer cells: Evidence for a
dose-window effect. Gynecol Oncol. 119:571–578. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Magliocco A and Egan C: Breast cancer
metastasis: Advances trough the use of in vitro co-culture model
systems. Breast Cancer - Focusing Tumor Microenvironment, Stem
Cells and Metastasis. Gunduz M and Gunduz E: InTech; Rijeka,
Croatia: 2011, View
Article : Google Scholar
|
|
38
|
Kim EJ and Helfman DM: Characterization of
the metastasis-associated protein, S100A4. Roles of calcium binding
and dimerization in cellular localization and interaction with
myosin. J Biol Chem. 278:30063–30073. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Leask A and Abraham DJ: All in the CCN
family: Essential matricellular signaling modulators emerge from
the bunker. J Cell Sci. 119:4803–4810. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jiang WG, Watkins G, Fodstad O,
Douglas-Jones A, Mokbel K and Mansel RE: Differential expression of
the CCN family members Cyr61, CTGF and Nov in human breast cancer.
Endocr Relat Cancer. 11:781–791. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Xie D, Nakachi K, Wang H, Elashoff R and
Koeffler HP: Elevated levels of connective tissue growth factor,
WISP-1, and CYR61 in primary breast cancers associated with more
advanced features. Cancer Res. 61:8917–8923. 2001.PubMed/NCBI
|
|
42
|
Jenkinson SR, Barraclough R, West CR and
Rudland PS: S100A4 regulates cell motility and invasion in an in
vitro model for breast cancer metastasis. Br J Cancer. 90:253–262.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Nguyen N, Kuliopulos A, Graham RA and
Covic L: Tumor-derived Cyr61(CCN1) promotes stromal matrix
metalloproteinase-1 production and protease-activated receptor
1-dependent migration of breast cancer cells. Cancer Res.
66:2658–2665. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lin J, Huo R, Wang L, Zhou Z, Sun Y, Shen
B, Wang R and Li N: A novel anti-Cyr61 antibody inhibits breast
cancer growth and metastasis in vivo. Cancer Immunol Immunother.
61:677–687. 2012. View Article : Google Scholar
|
|
45
|
Absenger Y, Hess-Stumpp H, Kreft B,
Krätzschmar J, Haendler B, Schütze N, Regidor PA and Winterhager E:
Cyr61, a deregulated gene in endometriosis. Mol Hum Reprod.
10:399–407. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Dhar A and Ray A: The CCN family proteins
in carcinogenesis. Exp Oncol. 32:2–9. 2010.PubMed/NCBI
|
|
47
|
Tsai MS, Bogart DF, Castañeda JM, Li P and
Lupu R: Cyr61 promotes breast tumorigenesis and cancer progression.
Oncogene. 21:8178–8185. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Tsai MS, Bogart DF, Li P, Mehmi I and Lupu
R: Expression and regulation of Cyr61 in human breast cancer cell
lines. Oncogene. 21:964–973. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Sampath D, Winneker RC and Zhang Z: Cyr61,
a member of the CCN family, is required for MCF-7 cell
proliferation: Regulation by 17beta-estradiol and overexpression in
human breast cancer. Endocrinology. 142:2540–2548. 2001.PubMed/NCBI
|
|
50
|
Buchholz S, Seitz S, Schally AV, Engel JB,
Rick FG, Szalontay L, Hohla F, Krishan A, Papadia A, Gaiser T, et
al: Triple-negative breast cancers express receptors for
luteinizing hormone-releasing hormone (LHRH) and respond to LHRH
antagonist cetrorelix with growth inhibition. Int J Oncol.
35:789–796. 2009.PubMed/NCBI
|
